What sector does Marksans Pharma Limited belong to?

Marksans Pharma Limited operates in the Healthcare sector, specifically the Pharmaceuticals industry, and is listed on the NSE.

What is the current share price of MARKSANS?

As of the latest available quote, MARKSANS traded at ₹329.95. This price is delayed and cached for about 15 minutes.

What is the P/E ratio of MARKSANS?

Marksans Pharma Limited has a price-to-earnings (P/E) ratio of about 28.94. The P/E ratio compares the share price to earnings per share and is most useful when compared with sector peers and the company's own history.

What is the market capitalisation of MARKSANS?

The market capitalisation of Marksans Pharma Limited is approximately ₹14,927 Cr.

Is Marksans Pharma Limited profitable?

For its latest reported financial year, Marksans Pharma Limited recorded a net profit margin of about 14.23%.

Does MARKSANS pay a dividend?

Marksans Pharma Limited does not currently show a dividend yield in our data.

What is the return on equity (ROE) of MARKSANS?

Marksans Pharma Limited has a return on equity (ROE) of about 15.20%. ROE measures how much profit a company generates relative to shareholders' equity.

What is the 52-week high and low of MARKSANS?

Over the past 52 weeks, MARKSANS has traded between a low of ₹155.00 and a high of ₹349.95.

Marksans Pharma Limited

MARKSANS NSE Healthcare Pharmaceuticals

Microcap 250

₹329.95

-0.14%

Delayed · cached 15 min

Fair value analysis

MARKSANS

Marksans Pharma Limited

₹330.40

Close used for this calculation

₹227.24Fair value

Financial DNA Score

Profitability · Returns · Balance Sheet · Efficiency · Growth

58/100

Profitability19/25

Returns10/25

Balance Sheet19/25

Efficiency10/25

Growth9/25

Good

Quality radar

Consensus fair value

₹227.24

Above FV

▼ -31.2% against the close used

Model range ₹131.07 – ₹350.16

The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear₹131.07Fair value₹227.24Bull₹350.16

FairClose

52-week traded range

52W low ₹156.8952W high ₹335.90

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading above the consensus fair value

Marksans Pharma Limited closed at ₹330.40, 45.4% above the consensus fair value of ₹227.24 drawn from 9 valuation models.

Financial DNA score 58/100 — Good. P/E of 28.9x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation

₹144.54

-56.3%

Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10

g=9%, r=10%, tg=3%, n=10yr

Graham Number

₹131.07

-60.3%

√(22.5 × EPS × BVPS)

EPS=9.22, BVPS=82.81 · outside Graham range (P/E 28.9, P/B 4) — asset-light, treat as a rough floor

Graham Formula

₹350.16

+6.0%

EPS × (8.5 + 2g) × 6.5 ÷ FD_Rate

g=16.2%, FD=7%

P/E Fair Value

₹329.15

-0.4%

EPS × 35.7x (sector P/E)

EPS=9.22, Sector P/E=35.7x

Peter Lynch (PEG)

₹149.36

-54.8%

EPS × Growth% (PEG = 1 is fair)

EPS=9.22, g=16.2%

EV/EBITDA

₹271.30

-17.9%

(EBITDA × 18x − Net Debt) ÷ Shares

EBITDA=7B

Book Value (P/B)

₹190.46

-42.4%

BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]

BVPS=82.81, ROE=15.2%, g=6%, r=10%

Reverse DCF

₹330.40

+0.0%

Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV

Implied: 15% | Historical: 16.2%

Margin of Safety

₹179.05

-45.8%

Avg(DCF, Graham, P/E) × 75% (25% safety buffer)

Avg fair value=238.73, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Fair value analysis

Consensus fair value

Price target range & 52-week position

Valuation summary

All valuation models

Equity Timer